Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 6/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | FAP | Q12884 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998597 | 0.79 | LMNA (0.36) | LMNATHRBCYP2C19 | |
| SCHEMBL5999934 | 0.72 | KMT2A (0.45) | DPP4DPP7DPP8 | |
| SCHEMBL1302820 | 0.72 | LMNA (0.44) | LMNATHRBCYP2C19 | |
| SCHEMBL3955359 | 0.65 | LMNA (0.39) | LMNATHRBCYP2C19 | |
| SCHEMBL3954238 | 0.65 | LMNA (0.36) | LMNATHRBCYP2C19 | |
| SCHEMBL1140605 | 0.63 | DPP4 (0.38) | CYP2C19DPP4DPP7FAPDPP8 | |
| SCHEMBL4765447 | 0.62 | LMNA (0.36) | LMNATHRBCYP2C19 | |
| SCHEMBL3949961 | 0.62 | LMNA (0.33) | LMNATHRBCYP2C19 | |
| SCHEMBL13002698 | 0.62 | DPP4 (0.41) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL6234024 | 0.61 | LMNA (0.35) | LMNATHRBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256310-A1 | Therapeutic compounds | REN, SLC5A1, SLC5A2 | LMNA 1574/4885THRB 2657/4885CYP2C19 257/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | LMNA 2178/4885THRB 1093/4885CYP2C19 1970/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | LMNA 2178/4885THRB 1093/4885CYP2C19 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.